Core Insights - ADMA Biologics, Inc. reported preliminary unaudited total revenue for FY 2024 between $417 million and $425 million, exceeding previous guidance of $415 million [1] - The company’s total cash holdings at year-end 2024 grew to over $100 million, reflecting a net cash surplus despite discharging $30 million of debt during Q4 2024 [1] - ADMA anticipates generating over $1 billion in total annual revenue prior to 2030, more than doubling the current 2025 revenue forecast [1][7] Financial Performance - FY 2025 and 2026 total revenue guidance is expected to exceed $485 million and $600 million, respectively [3][7] - FY 2025 and 2026 net income is expected to exceed $170 million and $230 million, respectively [3][7] - FY 2025 and 2026 adjusted EBITDA is expected to exceed $220 million and $300 million, respectively [3][7] Business Updates - Newly executed long-term high-titer plasma supply contracts are expected to support ASCENIV revenue growth through the late 2030s [2][7] - A Prior Approval Supplement (PAS) has been submitted to the FDA for an innovative yield enhancement production process, with potential regulatory approval anticipated by mid-2025 [2][7] - The innovative process is expected to increase Immunoglobulin (IG) yields by approximately 20%, driving revenue and earnings increases starting later in 2025 [2][7] Strategic Positioning - ADMA has solidified high-titer plasma supply on a long-term basis, increasing access to raw material plasma from approximately 250 collection centers, a five-fold increase in total collection capacity [7] - The company is focused on optimizing its balance sheet, having generated approximately $45 million in operating cash flow in Q4 2024, leading to a net cash surplus relative to its outstanding debt [7] - ADMA is leveraging its robust intellectual property estate and innovative R&D engine, with potential upside from its lead R&D pipeline program, SG-001, targeting S. pneumonia [7]

Core Viewpoint - ADMA Biologics has experienced a significant stock price increase of 275.7% over the past year, contrasting with a 14.3% decline in the industry, driven by strong quarterly performance and raised guidance [1][3]. Company Performance - ADMA Biologics specializes in plasma-derived biologics for treating immune deficiencies and preventing certain infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [4]. - The lead product, Asceniv, is a plasma-derived IVIG that contains polyclonal antibodies, indicated for treating primary immunodeficiency disease (PIDD) in adults and adolescents [5]. Financial Highlights - Total revenues in the third quarter increased by 78%, attributed to higher sales of Asceniv and third-party plasma sales from ADMA's BioCenters [6]. - ADMA has raised its revenue guidance for 2024 to over $415 million and for 2025 to over $465 million, with net income projections exceeding $120 million in 2024 and $165 million in 2025 [9]. Product Development - ADMA is conducting a pediatric study for Asceniv, which may lead to label expansion to include pediatric patients, with a potential application filing expected in the coming quarters [7][8]. Margin and Valuation - The higher-margin product portfolio now constitutes over 50% of total revenues, with plans to increase Asceniv's supply, potentially enhancing margins and earnings growth [10]. - ADMA's shares currently trade at a price/sales ratio of 8.86x forward sales, significantly higher than the industry average of 1.69x [11]. Market Outlook - The market for plasma-derived products has substantial growth potential, particularly in the underserved immune-compromised patient population [14].

Company Overview - ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3] - The company currently manufactures and markets three FDA-approved plasma-derived biologics: BIVIGAM, ASCENIV™, and NABI-HB, targeting immune deficiencies and prevention of certain infectious diseases [3] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and also runs ADMA BioCenters, an FDA-approved source plasma collector [3] Upcoming Events - Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, from January 13-16, 2025, with ADMA's presentation scheduled for January 13, 2025, at 10:30 a.m. PT [1] - A live audio webcast of the presentation will be available on the company's investor website, with an archived version accessible approximately two hours after the event [2]

Industry Overview - Innovation is expected to drive growth in the biotech industry, particularly in obesity and oncology drugs, with strong M&A activity anticipated in 2025 [1] - The overall fundamentals of the biotech sector remain robust, and investor interest is expected to return [1][16] ADMA Biologics - ADMA Biologics markets plasma-derived biologics for immune deficiencies and infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [2] - The company has shown exceptional performance in 2024, with shares increasing by 292% year to date [3] - Earnings per share estimates for 2025 have risen from 64 cents to 78 cents in the last 60 days [4] - ADMA is working to increase Asceniv's supply, which is expected to significantly contribute to total revenues and margin expansion [20] Tarsus Pharmaceuticals - Tarsus Pharmaceuticals markets Xdemvy, an eye drop for Demodex blepharitis, which generated $113.7 million in sales in the first nine months of 2024 [5][22] - The company has experienced a share price increase of 168.7% in 2024, supported by positive regulatory updates and pipeline progress [7][23] - Loss per share estimates for 2025 have narrowed from $2.10 to $1.43 in the past 60 days [7] Stoke Therapeutics - Stoke Therapeutics is developing zorevunersen for Dravet syndrome, currently in phase I/IIa studies, with Breakthrough Therapy designation granted by the FDA [8][9] - The company has seen a share price increase of 120.7% year to date, with expectations for further gains in 2025 [11][26] - Loss per share estimates for 2025 have narrowed from $2.59 to $2.49 in the past 60 days [11] ChromaDex - ChromaDex markets Niagen as a leading NAD+ booster and is developing nicotinamide riboside chloride (NRC) for ataxia telangiectasia, with FDA designations granted [12][14] - The company has experienced a share price increase of 270.6% in 2024, driven by strong sales and e-commerce growth [15][28] - Earnings per share estimates for 2025 have increased from 9 cents to 12 cents in the past 60 days [15]

Core Insights - ADMA Biologics has repaid $30 million of its senior secured term loan facility, reducing total gross debt to $75 million, which represents a 29% reduction from previous levels [1][5] - The repayment was funded using cash on hand, indicating strong cash flow generation capabilities [2] - The company anticipates that the reduction in debt will lower interest expenses and enhance earnings growth potential in the near future [2] Company Overview - ADMA Biologics is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [2] - The company currently markets three FDA-approved plasma-derived biologics: BIVIGAM®, ASCENIV™, and NABI-HB® [2] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, that collects source plasma [2]

Industry Overview - The biotech sector experienced volatility in 2024, starting positively but declining by 10.5% due to a slowdown in collaboration deals despite new drug approvals and increased M&A activity [1] - The continuous demand for innovative medical treatments is expected to keep investor interest in the biotech industry, despite macroeconomic uncertainties [2] M&A Activity - M&A activity is anticipated to accelerate in 2025 due to a change in administration and expected deregulation, with major pharma and biotech companies looking to enhance their product portfolios [3] - Companies focusing on oncology, immunooncology, obesity drugs, and gene-editing are likely to attract attention, benefiting smaller biotech firms with promising candidates [3] Company Highlights Sarepta Therapeutics (SRPT) - Sarepta's portfolio was significantly enhanced by the FDA approval of Elevidys, the first gene therapy for Duchenne muscular dystrophy (DMD), which has shown blockbuster potential [5] - The company is developing additional gene therapy programs and plans to submit a regulatory filing for its LGMD candidate in mid-2025 [6] - Sarepta's shares surged 24.7% in 2024, with a current average target price of $184.15, indicating a potential upside of 46.43% [7] ADMA Biologics (ADMA) - ADMA markets plasma-derived biologics for immune deficiencies, with Asceniv showing strong sales growth and potential label expansion for pediatric patients [9][10] - The higher-margin product portfolio now constitutes over 50% of total revenues, with shares increasing by 291.6% in 2024 [11] - The current average target price for ADMA is $25, representing an upside of 34.19% [12] Exelixis (EXEL) - Exelixis has performed well due to its lead drug, Cabometyx, which is a leading treatment for renal cell carcinoma [13] - The FDA accepted a supplemental new drug application for Cabometyx, with a target action date of April 3, 2025, which could enhance growth prospects [14] - Shares have increased by 40.3% in 2024, with EPS estimates rising for 2024 and 2025 [16] Alnylam Pharmaceuticals (ALNY) - Alnylam's marketed drugs, including Amvuttra, are performing well, with efforts to expand Amvuttra's label to boost sales [17] - The company has collaborations with major firms to advance its pipeline, which includes promising candidates like cemdisiran and mivelsiran [18] - Alnylam's shares have surged 24.3% year to date, with a current average target price of $296.32, indicating a potential upside of 24.55% [19]

Core Viewpoint - Adma Biologics (ADMA) has seen a 5.8% increase in share price over the past four weeks, closing at $19.92, with analysts suggesting a potential upside of 25.5% based on a mean price target of $25 [1] Price Targets - The average price target for ADMA ranges from a low of $24 to a high of $26, with a standard deviation of $0.82, indicating a relatively tight clustering of estimates [2] - The lowest estimate suggests a 20.5% increase from the current price, while the highest estimate indicates a 30.5% upside [2] Analyst Sentiment - Analysts show strong agreement regarding ADMA's potential for better earnings, as indicated by positive revisions in earnings estimates, which historically correlate with stock price movements [4][9] - The Zacks Consensus Estimate for the current year has risen by 5.4% over the past month, with three estimates increasing and no negative revisions [10] Zacks Rank - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [11] Conclusion on Price Targets - While consensus price targets may not be entirely reliable for predicting stock price movements, the direction indicated by these targets can serve as a useful guide for further research [12]

Core Viewpoint - Adma Biologics (ADMA) shares have increased by 20.7% in the past four weeks, closing at $19.04, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $25, representing a 31.3% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.82, where the lowest estimate of $24 indicates a 26.1% increase, and the highest estimate suggests a 36.6% surge to $26 [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [7] Earnings Estimates and Market Sentiment - Analysts are optimistic about ADMA's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - Over the last 30 days, three earnings estimates for ADMA have been revised upward, leading to a 5.4% increase in the Zacks Consensus Estimate [10] - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11] Caution on Price Targets - While price targets are often sought after by investors, they can mislead, as empirical research shows that they rarely indicate actual stock price movements [5] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [8][12]

LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ: ADMA) for violations of the securities laws.According to the Complaint, the Company made false and misleading statements to the market. ADMA Biologics admitted the abrupt resignation of its independent outside auditor, CohnReznick LLP., on October 9, 2024. The Company ...

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...